Table 2.
Baseline characteristics: EASI erythema, infiltration/papulation, excoriation, and lichenification scores
| Score range | LIBERTY AD PEDS, aged ≥ 6 to < 12 years | LIBERTY AD ADOL, aged ≥ 12 to < 18 years | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall (n = 304) |
Placebo + TCS < 30 kg (n = 61) |
Dupilumab 300 mg q4w + TCS < 30 kg (n = 61) |
Placebo + TCS ≥ 30 kg (n = 62) |
Dupilumab 200 mg q2w + TCS ≥ 30 kg (n = 59) |
Dupilumab 300 mg q4w + TCS ≥ 30 kg (n = 61) |
Overall (n = 167) |
Placebo < 60 kg (n = 43) |
Dupilumab 200 mg q2w < 60 kg (n = 43) |
Placebo ≥ 60 kg (n = 42) |
Dupilumab 300 mg
q2w ≥ 60 kg (n = 39) |
||
| EASI erythema score | ||||||||||||
| Head and neck, mean (SD) | 0–18 | 8.0 (4.5) | 8.8 (5.0) | 8.4 (4.6) | 7.9 (4.3) | 7.6 (3.8) | 7.4 (4.8) | 8.2 (4.4) | 8.6 (4.3) | 7.8 (4.5) | 8.0 (5.1) | 8.2 (3.7) |
| Trunk, mean (SD) | 0–18 | 7.8 (4.6) | 7.7 (4.7) | 7.6 (4.6) | 8.4 (4.4) | 7.4 (4.7) | 7.9 (4.9) | 8.2 (4.8) | 7.7 (5.1) | 7.8 (5.1) | 8.7 (4.6) | 8.6 (4.2) |
| Upper extremities, mean (SD) | 0–18 | 10.9 (3.8) | 10.9 (3.7) | 10.2 (4.0) | 11.4 (3.9) | 10.5 (3.5) | 11.5 (3.8) | 10.1 (4.2) | 10.3 (4.2) | 9.7 (4.4) | 10.5 (3.9) | 9.9 (4.2) |
| Lower extremities, mean (SD) | 0–18 | 11.3 (3.9) | 12.0 (3.7) | 10.8 (3.8) | 11.2 (4.0) | 11.4 (3.9) | 11.3 (4.0) | 9.7 (4.5) | 9.4 (4.7) | 10.5 (4.6) | 9.4 (4.5) | 9.2 (4.1) |
| EASI infiltration/papulation score | ||||||||||||
| Head and neck, mean (SD) | 0–18 | 6.9 (4.3) | 7.3 (4.48) | 7.5 (4.3) | 6.6 (4.2) | 6.5 (4.1) | 6.5 (4.5) | 7.1 (4.3) | 7.6 (4.2) | 7.1 (4.4) | 6.5 (4.5) | 7.3 (4.1) |
| Trunk, mean (SD) | 0–18 | 7.7 (4.8) | 8.0 (4.76) | 7.6 (4.6) | 8.5 (4.5) | 7.1 (5.2) | 7.4 (4.8) | 7.9 (4.6) | 8.0 (5.1) | 7.5 (4.9) | 8.2 (4.4) | 8.1 (4.1) |
| Upper extremities, mean (SD) | 0–18 | 10.9 (3.7) | 11.1 (3.9) | 10.3 (3.7) | 11.4 (3.9) | 10.4 (3.7) | 11.3 (3.4) | 10.1 (4.1) | 10.5 (4.5) | 9.4 (3.8) | 10.3 (3.9) | 10.1 (4.2) |
| Lower extremities, mean (SD) | 0–18 | 11.4 (3.9) | 11.9 (4.0) | 11.1 (3.9) | 11.1 (4.0) | 11.3 (3.7) | 11.5 (4.0) | 9.9 (4.5) | 9.9 (5.0) | 10.4 (4.2) | 9.9 (4.6) | 9.2 (4.5) |
| EASI excoriation score | ||||||||||||
| Head and neck, mean (SD) | 0–18 | 6.1 (4.5) | 6.6 (4.8) | 6.7 (4.7) | 6.1 (4.5) | 5.3 (3.7) | 5.7 (4.5) | 6.0 (4.7) | 5.9 (4.8) | 6.0 (5.0) | 6.0 (4.8) | 6.0 (4.5) |
| Trunk, mean (SD) | 0–18 | 6.7 (4.8) | 6.7 (4.9) | 6.7 (4.6) | 7.3 (4.8) | 6.5 (5.2) | 6.5 (4.6) | 7.3 (5.0) | 7.3 (5.4) | 7.1 (5.4) | 7.9 (4.7) | 7.0 (4.6) |
| Upper extremities, mean (SD) | 0–18 | 10.6 (4.1) | 10.7 (4.3) | 10.3 (4.1) | 10.8 (4.2) | 10.1 (4.2) | 11.1 (3.9) | 9.9 (4.3) | 10.2 (4.6) | 9.3 (4.3) | 10.4 (3.7) | 9.9 (4.5) |
| Lower extremities, mean (SD) | 0–18 | 11.2 (4.0) | 11.7 (3.8) | 10.8 (4.1) | 11.0 (3.8) | 11.1 (4.1) | 11.1 (4.3) | 9.5 (4.8) | 8.6 (5.2) | 10.5 (4.4) | 9.9 (4.6) | 9.0 (5.0) |
| EASI lichenification score | ||||||||||||
| Head and neck, mean (SD) | 0–18 | 7.0 (4.6) | 7.4 (4.5) | 7.8 (4.9) | 6.7 (4.3) | 6.8 (4.4) | 6.2 (4.9) | 6.5 (4.2) | 7.1 (4.7) | 6.1 (4.3) | 6.0 (4.2) | 6.6 (3.7) |
| Trunk, mean (SD) | 0–18 | 7.1 (4.7) | 7.6 (4.6) | 7.2 (4.5) | 7.8 (4.9) | 6.5 (4.8) | 6.5 (5.0) | 7.1 (4.9) | 7.2 (5.4) | 7.1 (4.7) | 7.4 (5.5) | 6.7 (4.2) |
| Upper extremities, mean (SD) | 0–18 | 11.1 (3.8) | 11.3 (3.9) | 10.7 (3.9) | 11.5 (3.8) | 10.9 (3.3) | 11.3 (3.8) | 10.0 (4.5) | 9.8 (5.0) | 10.0 (4.4) | 10.3 (4.5) | 10.0 (4.2) |
| Lower extremities, mean (SD) | 0–18 | 11.6 (4.1) | 12.6 (3.7) | 11.2 (4.3) | 11.8 (4.1) | 11.1 (3.7) | 11.1 (4.4) | 9.5 (4.8) | 9.4 (5.1) | 10.6 (4.6) | 9.3 (4.9) | 8.7 (4.3) |
EASI Eczema Area and Severity Index, q2w every 2 weeks, q4w every 4 weeks, SD standard deviation, TCS topical corticosteroid